Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CTSG | P08311 | 2/20 | 0.53 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | CTRC | Q99895 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189455 | 1.00 | ELANE (0.56) | ELANEMEN1KMT2ACTSGPRTN3 | |
| SCHEMBL10068628 | 0.81 | ALDH1A1 (0.54) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL9909016 | 0.79 | ELANE (0.59) | ELANEMEN1KMT2ACTSGPRTN3 | |
| SCHEMBL12469648 | 0.79 | ELANE (0.59) | ELANEMEN1KMT2ACTSGPRTN3 | |
| SCHEMBL9975770 | 0.76 | KMT2A (0.66) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL10031595 | 0.76 | KMT2A (0.66) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL16775234 | 0.75 | KMT2A (0.70) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL16759895 | 0.75 | KMT2A (0.70) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL22647700 | 0.74 | KMT2A (0.68) | ELANEMEN1KMT2ACTSGALDH1A1 | |
| SCHEMBL6620106 | 0.73 | ELANE (0.53) | ELANEMEN1KMT2ACTSGPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696574-B2 | N-(INDOLE-2-CARBONYL)-BETA-ALANINAMIDE DERIVATIVES | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030187051-A1 | Anticholesterol agents, cardiovascular disorders, hypotensive agents, antidiabetic agents, antitumor agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187051-A1 | Anticholesterol agents, cardiovascular disorders, hypotensive agents, antidiabetic agents, antitumor agents | PYGL, PYGM, AGL | ELANE 4083/4885MEN1 1506/4885KMT2A 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.